Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.09.17	Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union (PR Newswire)
21.09.17	ELOQUII Debuts Exclusive Capsule Collection With Digital Influencer & Style Expert, Katie Sturino (PR Newswire)
16.09.17	Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis (PR Newswire)
14.09.17	Stocks Under Scanner in the Biotech Space -- Puma Biotech, Regeneron Pharma, Sarepta Therapeutics, and Seattle Genetics (PR Newswire)
13.09.17	Smart Medical Device Could Save Millions of Lives (PR Newswire)
12.09.17	Companies to Watch as Biotech Makes a Comeback in 2017 (PR Newswire)
11.09.17	Sanofi, Regeneron: Dupilumab Meets Main Objectives In Late-Stage Asthma Trial (RTTNews)
11.09.17	Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma (PR Newswire)
31.08.17	Regeneron Announces Upcoming Investor Conference Presentations (PR Newswire)
28.08.17	Ellen L. Behrens is recognized by Continental Who's Who (PR Newswire)
25.08.17	Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017 (PR Newswire)
23.08.17	Luxe Interiors + Design Names New Group Publisher And Chief Revenue Officer (PR Newswire)
23.08.17	ALM Intelligence Names KPMG a Global 'Leader' in Employee Experience Consulting (PR Newswire)
15.08.17	FDA Lifts Hold On CVM's Study, FATE On Track, REGN, OPHT, ZYNE All Flunk Trials (RTTNews)
14.08.17	Regeneron To Discontinue Development Of Suptavumab For RSV; Stock Down (RTTNews)
14.08.17	Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus (PR Newswire)
03.08.17	Options Trades for Allergan, 3D Systems, Regeneron Pharmaceuticals, Tesla Motors and Yelp include trade ideas that offer returns of 26% or more! (PR Newswire)
03.08.17	Regeneron Pharmaceuticals Profit Rises 48% In Q2 (RTTNews)
03.08.17	Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast (PR Newswire)
03.08.17	Regeneron Q2 Results Top Estimates; Lifts FY View For EYLEA U.S. Sales Growth (RTTNews)
03.08.17	Regeneron Reports Second Quarter 2017 Financial and Operating Results (PR Newswire)
26.07.17	Generali Global Assistance Publishes White Paper On The Benefits Of Adding Identity Protection Services To Customer Loyalty Programs (PR Newswire)
24.07.17	One Step Closer To EU Approval... (RTTNews)
21.07.17	Regeneron, Sanofi Get Positive CHMP Opinion For Dupixent - Quick Facts (RTTNews)
21.07.17	Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
13.07.17	Regeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017 (PR Newswire)
13.07.17	Regeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation (PR Newswire)
10.07.17	Daily Technical Summary Reports on Biotech Stocks -- PTC Therapeutics, Portola Pharma, Regeneron Pharma, and Seattle Genetics (PR Newswire)
27.06.17	Regeneron: EC Okays Kevzara To Treat Moderately To Severely Active RA (RTTNews)
27.06.17	Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union (PR Newswire)
21.06.17	Regeneron Recognized on "The Civic 50" List of the Most Community-Minded Companies in the United States (PR Newswire)
12.06.17	LXRX Brings Sweet Tidings, PFE's PROSPER Ahead Of Schedule, XBIT Fails To Excite (RTTNews)
12.06.17	Sanofi Announces Results From Two Phase 3b/4 ODYSSEY-DM Trials In Diabetes (RTTNews)
11.06.17	Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia (PR Newswire)
11.06.17	Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia (PR Newswire)
04.06.17	Regeneron, Sanofi Present Positive Study Results For PD-1 Antibody REGN2810 (RTTNews)
04.06.17	Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
24.05.17	Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH (PR Newswire)
22.05.17	Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (PR Newswire)
22.05.17	Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (PR Newswire)
18.05.17	AWO Welcomes Inclusion of Vessel Discharge Reform, Waterway Tender Recapitalization in Coast Guard Authorization Bill (PR Newswire)
18.05.17	Regeneron Announces Upcoming Investor Conference Presentations (PR Newswire)
08.05.17	Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer (PR Newswire)
08.05.17	Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy (PR Newswire)
05.05.17	Regeneron Announces Upcoming Investor Conference Presentations (PR Newswire)
04.05.17	Regeneron Extending Recent Strong Move To The Upside (RTTNews)
04.05.17	Regeneron Pharmaceuticals Profit Rises 23% In Q1 (RTTNews)
04.05.17	Regeneron Reports First Quarter 2017 Financial and Operating Results (PR Newswire)
02.05.17	Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment (PR Newswire)
02.05.17	Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone
05.12.24		Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer
19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

17.12.24

Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge

17.12.24

Minuszeichen in New York: NASDAQ 100 verliert nachmittags

17.12.24

Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer

12.12.24

Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone

05.12.24

Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Regeneron Pharmaceuticals Inc.

Aktien Top/Flop

Regeneron Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten